The Terminus Notes

About

About The Terminus Notes

A neutral, evidence-first record of what is actually known about peptides and research chemicals — mechanisms, trial data, safety signals, and regulatory status — reported without persuasion.

What this is

The Terminus Notes presents what is known about peptides and research chemicals — accurately, and without persuasion — so that readers can form their own conclusions. It reports. It does not recommend, promote, sell, or facilitate the acquisition or use of any compound.

The test applied to every page is simple: would a sceptical pharmacologist and a regulator both agree this is a fair description of the evidence, with nothing tilted toward use? If not, it is not published.

Many compounds discussed here are unlicensed, investigational, or available by prescription only. That status is reported plainly on each page; it is not a recommendation either for or against.

How it works

  • Report, don't recommendDescribe what the evidence shows. Never tell a reader to take, dose, source, or cycle anything.
  • Evidence over enthusiasmClaims are proportioned to evidence quality. Thin evidence is stated as thin, even when a compound is popular.
  • Neutrality is structuralIt comes from sourcing discipline and honest grading — not from adding a disclaimer to promotional copy.
  • Fact and opinion separateNeutral evidence pages and clearly labelled opinion are kept visibly distinct, and never blurred.
  • Honesty about absence"No registered human trials exist" is a finding worth stating plainly. Absence of evidence is reported, not glossed.
  • No supply, no steeringNo commercial relationship with any seller, and no links to, favourable naming of, or steering toward vendors.

How evidence is graded

Every monograph grades each claim or use-case separately — a compound can be well-supported for one endpoint and unsupported for another. Grades describe the certainty of the evidence, not whether a compound is good or bad, and they are deliberately not colour-coded so that styling never reads as a recommendation.

Where a strong-looking result has only been announced — a sponsor press release, a conference abstract, an un-reviewed preprint — it is flagged as topline and capped until it is published in full. A claim you cannot yet inspect is not treated as a settled finding. The How to read this resource page explains the grades in full.

Why the author is anonymous

This resource is written under a pseudonym, and it asks to be judged on its method rather than on its author. Every substantive claim is traceable to a primary source you can open and check yourself; the grading rubric is published and applied consistently. That is the basis for trusting it — not credentials, and not identity.

Anonymity also keeps the focus where it belongs: on the evidence, not the person describing it. No page references the author's name, location, employer, professional registration, or any related brand.

Conflicts of interest

The Terminus Notes sells no compounds, holds no affiliate or commercial relationship with any vendor of the compounds discussed, and earns no commission on any sale. If monetisation is ever added, it will be disclosed here honestly and kept decoupled from supply. This statement is part of the record, not a formality.

Scope

In scope

  • Mechanisms of action
  • Pharmacokinetics & pharmacodynamics
  • Preclinical and clinical trial data
  • Safety and adverse-event data
  • Regulatory and legal status
  • Evidence quality and how to read it
  • Analytical / QC topics (COA, HPLC, HRMS)

Out of scope

  • Dosing protocols or schedules as guidance
  • Sourcing, vendors, or purchasing
  • Reconstitution presented as instruction
  • Any framing that assumes or encourages human use of unlicensed compounds